TrialThe oncologist2019

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

Daniel J George et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.